Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697873 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1698022 | 0.80 | IKBKB (0.42) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL14302410 | 0.79 | TP53 (0.42) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL21457814 | 0.79 | KDM4E (0.63) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7847882 | 0.78 | KDM4E (0.48) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL9543622 | 0.78 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL7536279 | 0.77 | CISD2 (0.47) | KDM4EALDH1A1GAAHPGDMAPT | |
| SCHEMBL2896095 | 0.77 | IKBKB (0.68) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL843791 | 0.77 | LIMK1 (0.68) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL26026228 | 0.77 | IKBKB (0.57) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278978-A1 | THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230278978-A1 | THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230278978-A1 | THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4185381-A1 | THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1847541-A1 | FUSED PYRIMIDINE DERIVATIVE AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | KDM4E 1129/4885ALDH1A1 1026/4885GLA 2681/4885 |
| US-20230278978-A1 | THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B1, HSD17B13 | KDM4E 2966/4885ALDH1A1 237/4885GLA 3186/4885 |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | GNRHR, FSHR, NPY4R | KDM4E 1719/4885ALDH1A1 4008/4885GLA 4238/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | KDM4E 1129/4885ALDH1A1 1026/4885GLA 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.